CHARLES F LEVENBACK to Adult
This is a "connection" page, showing publications CHARLES F LEVENBACK has written about Adult.
Connection Strength
0.513
-
A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):275-9.
Score: 0.018
-
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol. 2013 Feb; 128(2):204-8.
Score: 0.016
-
"Triple injection" lymphatic mapping technique to determine if parametrial nodes are the true sentinel lymph nodes in women with cervical cancer. Gynecol Oncol. 2012 Dec; 127(3):467-71.
Score: 0.016
-
Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer. Gynecol Oncol. 2012 Oct; 127(1):18-21.
Score: 0.016
-
Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008 Mar; 108(3):478-81.
Score: 0.012
-
Retroperitoneal lymph node resection in patients with cervical cancer. Surg Oncol. 2006 Aug; 15(2):79-83.
Score: 0.011
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.011
-
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol. 2006 Apr; 194(4):1186-93; discussion 1193-5.
Score: 0.010
-
Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol. 2006 Sep; 102(3):534-6.
Score: 0.010
-
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2006 Aug; 102(2):252-5.
Score: 0.010
-
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
Score: 0.010
-
Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. Obstet Gynecol. 2005 Mar; 105(3):514-8.
Score: 0.010
-
Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer. 2004 Nov-Dec; 14(6):1070-7.
Score: 0.009
-
Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004 Oct; 95(1):133-8.
Score: 0.009
-
Radical trachelectomy: is it here to stay? Gynecol Oncol. 2004 Sep; 94(3):611-3.
Score: 0.009
-
Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecol Oncol. 2004 Sep; 94(3):746-53.
Score: 0.009
-
Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer. 2004 Jul-Aug; 14(4):580-8.
Score: 0.009
-
Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecol Oncol. 2004 Jan; 92(1):205-10.
Score: 0.009
-
The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):409-18.
Score: 0.009
-
Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecol Oncol. 2003 Sep; 90(3):625-8.
Score: 0.009
-
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002 Feb 01; 20(3):688-93.
Score: 0.008
-
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81.
Score: 0.008
-
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
Score: 0.007
-
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
Score: 0.007
-
Intraoperative lymphatic mapping and sentinel node identification: gynecologic applications. Recent Results Cancer Res. 2000; 157:150-8.
Score: 0.007
-
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
Score: 0.006
-
Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecol Oncol. 2017 04; 145(1):96-101.
Score: 0.005
-
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
Score: 0.005
-
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
Score: 0.005
-
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
Score: 0.005
-
Arterial occlusion complicating treatment of gynecologic cancer: a case series. Gynecol Oncol. 1996 Oct; 63(1):40-6.
Score: 0.005
-
Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education. Gynecol Oncol. 2016 Jan; 140(1):114-9.
Score: 0.005
-
Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol Oncol. 1995 Nov; 59(2):216-20.
Score: 0.005
-
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7.
Score: 0.005
-
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6.
Score: 0.005
-
Improved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence. Int J Gynecol Cancer. 2015 Jan; 25(1):152-9.
Score: 0.005
-
Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
Score: 0.005
-
Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol. 2015 Jan; 136(1):65-70.
Score: 0.005
-
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55.
Score: 0.005
-
Enterovesical fistula following radiotherapy for gynecologic cancer. Gynecol Oncol. 1994 Mar; 52(3):296-300.
Score: 0.004
-
Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1045-50.
Score: 0.004
-
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992 Sep; 46(3):317-21.
Score: 0.004
-
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805.
Score: 0.004
-
Risk factors for prolonged hospitalization after gynecologic laparoscopic surgery. Gynecol Oncol. 2012 Sep; 126(3):428-31.
Score: 0.004
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.004
-
Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol. 2012 Apr; 125(1):241-4.
Score: 0.004
-
The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer. 2012 Jan; 22(1):123-31.
Score: 0.004
-
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. Int J Gynecol Cancer. 2011 Oct; 21(7):1266-75.
Score: 0.004
-
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol. 2011 Nov; 123(2):333-6.
Score: 0.004
-
Work related stress among gynecologic oncologists. Gynecol Oncol. 2011 Nov; 123(2):365-9.
Score: 0.004
-
Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec; 116(6):1358-1365.
Score: 0.004
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.004
-
Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
Score: 0.003
-
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. Int J Gynecol Cancer. 2010 Apr; 20(3):353-7.
Score: 0.003
-
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010 Mar 11; 3:9.
Score: 0.003
-
What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72.
Score: 0.003
-
Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol. 2009 Jul; 114(1):93-99.
Score: 0.003
-
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May; 113(2):210-5.
Score: 0.003
-
Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment. Support Care Cancer. 2009 Sep; 17(9):1195-201.
Score: 0.003
-
Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol. 2008 Nov-Dec; 15(6):723-8.
Score: 0.003
-
Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. Am J Surg Pathol. 2008 Sep; 32(9):1336-43.
Score: 0.003
-
A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol. 2008 Sep-Oct; 15(5):584-8.
Score: 0.003
-
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008 Jul; 110(1):56-9.
Score: 0.003
-
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71.
Score: 0.003
-
Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer. 2008 May-Jun; 18(3):571-5.
Score: 0.003
-
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1081-7.
Score: 0.003
-
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8.
Score: 0.003
-
Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006 Dec; 103(3):888-90.
Score: 0.003
-
Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006 May-Jun; 16(3):1106-11.
Score: 0.003
-
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer. 2006 May-Jun; 16(3):1165-71.
Score: 0.003
-
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005 Oct 20; 23(30):7428-36.
Score: 0.003
-
Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol. 2005 Oct; 9(5):289-92.
Score: 0.002
-
Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):138-47.
Score: 0.002
-
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):442-8.
Score: 0.002
-
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004 Jun; 33(12):1219-24.
Score: 0.002
-
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004 Apr; 93(1):27-33.
Score: 0.002
-
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004 Mar 01; 22(5):872-80.
Score: 0.002
-
Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol. 2004 Feb; 92(2):586-91.
Score: 0.002
-
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol. 2004 Jan; 92(1):365-7.
Score: 0.002
-
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
Score: 0.002
-
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003 Jan 15; 21(2):291-7.
Score: 0.002
-
Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol. 2002 Sep 01; 20(17):3651-7.
Score: 0.002
-
Trends among gynecologic oncology inpatient deaths: is end-of-life care improving? Gynecol Oncol. 2002 May; 85(2):356-61.
Score: 0.002
-
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33.
Score: 0.002
-
Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol. 2001 Jul; 82(1):150-5.
Score: 0.002
-
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001 May; 81(2):237-41.
Score: 0.002
-
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001 May; 81(2):213-5.
Score: 0.002
-
Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000 Aug; 78(2):187-93.
Score: 0.002
-
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.
Score: 0.002
-
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300.
Score: 0.002
-
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999 Apr; 73(1):35-41.
Score: 0.002
-
Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998 Nov 15; 83(10):2157-63.
Score: 0.002
-
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1998 Sep; 70(3):334-8.
Score: 0.002
-
A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol Oncol. 1998 Aug; 70(2):215-8.
Score: 0.002
-
Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 1998 May; 16(5):1879-84.
Score: 0.001
-
Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar; 16(3):1094-8.
Score: 0.001
-
Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997 Jan; 64(1):13-7.
Score: 0.001
-
Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer. 1996 Nov 15; 78(10):2229-35.
Score: 0.001
-
Transverse colon urinary diversion in gynecologic oncology. Gynecol Oncol. 1996 Oct; 63(1):66-70.
Score: 0.001
-
Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. Obstet Gynecol. 1996 Jul; 88(1):82-6.
Score: 0.001
-
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996 May; 14(5):1552-7.
Score: 0.001
-
Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol. 1996 Apr; 87(4):527-31.
Score: 0.001
-
Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC). Gynecol Oncol. 1995 Nov; 59(2):211-5.
Score: 0.001
-
Adenocarcinoma of the cervix in a renal transplant patient. Gynecol Oncol. 1995 Oct; 59(1):151-5.
Score: 0.001
-
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 1995 Oct; 59(1):51-6.
Score: 0.001
-
Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 1995 Sep; 58(3):349-55.
Score: 0.001
-
Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol. 1995 Aug; 58(2):189-93.
Score: 0.001
-
Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol. 1995 Aug; 58(2):202-5.
Score: 0.001
-
Pelvic exenteration for adenocarcinoma of the uterine cervix. Gynecol Oncol. 1995 Jul; 58(1):74-8.
Score: 0.001
-
Ovarian malignant mixed m?llerian tumors treated with platinum-based chemotherapy. Obstet Gynecol. 1995 May; 85(5 Pt 1):735-9.
Score: 0.001
-
Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20.
Score: 0.001
-
Perineal reconstruction using single gracilis myocutaneous flaps. Gynecol Oncol. 1995 May; 57(2):221-5.
Score: 0.001
-
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy. Gynecol Oncol. 1995 Apr; 57(1):72-8.
Score: 0.001
-
Closure of complex vulvar defects using local rhomboid flaps. Obstet Gynecol. 1994 Dec; 84(6):1043-7.
Score: 0.001
-
Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol. 1994 Dec; 12(12):2737-42.
Score: 0.001
-
Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol. 1994 Nov; 55(2):217-23.
Score: 0.001
-
Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994 Oct; 55(1):47-50.
Score: 0.001
-
A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. Gynecol Oncol. 1994 May; 53(2):234-8.
Score: 0.001
-
Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol. 1993 Dec; 51(3):397-400.
Score: 0.001